๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chongqing
Clinical trial register · China

Clinical Trials in Chongqing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca99 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC38 First Affiliated Hospital of Chongqing Medical University37 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chongqing

1056 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
NCT07557927Discoid Lupus Erythematosus
Kunming Pharmaceuticals, Inc.
Phase 2
100
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou
2026-04-30
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161Alzheimer Disease
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537Cutaneous Lupus Erythematosus (CLE)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
Recruiting
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
NCT07520162Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Foshan
2026-04-24
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
NCT07470983Primary Aldosteronism
Shandong Suncadia Medicine Co., Ltd.
Phase 2
60
Chongqing, Zhengzhou
2026-04-23
Not yet open
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599Ischemic Cerebral Infarction
Beijing Tiantan Hospital
Phase 3
4,810
Fuyang, Wuhu, Beijing, Chongqing, Ningde, Dingxi, Jiuquan, Lanzhou
2026-04-22
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Changsha, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan
2026-04-22
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Changzhou, Chongqing, Guangzhou, Nanjing, Wuhan
2026-04-21
Active, closed
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations
NCT07338942ATTR-CM
AstraZeneca
Not applicable
4,000
Beijing, Changlexi, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangdong Province
2026-04-21
Recruiting
Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
NCT06201013Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge
Children's Hospital of Chongqing Medical University
Not applicable
180
Chongqing
2026-04-20
Recruiting
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
NCT07588880Progressive Familial Intrahepatic Cholestasis
Ipsen
Observational
20
Beijing, Chongqing, Hunan, Nanjing, Shanghai, Xiamen
2026-04-16
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-04-15
Recruiting
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
NCT07496229T-cell Lymphomas
Dizal Pharmaceuticals
Phase 1/2
165
Chongqing, Fuzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Chengdu, Taizhou
2026-04-15
Recruiting
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07493135Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1
30
Beijing, Chongqing, Shanghai, Zhengzhou
2026-04-14
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
NCT07468630Colon Adenocarcinoma
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
106
Chongqing
2026-04-10
Recruiting
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
NCT07448922Advanced Gynecological Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
280
Chongqing, Shanghai
2026-04-08
By invitation
Autologous Platelet Concentrate Bladder Injection for Refractory Overactive Bladder
NCT07797647Over Active Bladder
Gang Chen
Observational
50
Chongqing
2026-04-08
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Recruiting
Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
NCT07338175Intracerebral Hemorrhage
Beijing Tiantan Hospital
Phase 3
1,192
Beijing, Chongqing, Guangzhou, Baoding, Zhangjiakou, Zunhua, Mengzhou, Nanle
2026-04-02
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177Alveolar Soft Part Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Not yet open
Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy
NCT07563075Hypoxemia, Pneumonia, Pulmonary Neoplasm
Zhejiang University
Not applicable
430
Hangzhou, Wenzhou, Chongqing
2026-04-01
Not yet open
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment
NCT07459179Interstitial Lung Disease
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
50
Chongqing
2026-04-01
Not yet open
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07459192Canser
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
50
Chongqing
2026-04-01
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803Plexiform Neurofibroma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
177
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang
2026-03-31
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014Systemic Lupus Erythematosus
Eisai Co., Ltd.
Phase 2
256
Bengbu, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Guiyang, Luoyang
2026-03-31
Recruiting
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
NCT07455734Advanced Solid Tumor Cancer
BioNTech SE
Phase 1/2
533
Chongqing, Guangzhou, Hangzhou, Shanghai, Tianjin
2026-03-30
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Recruiting
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
NCT07487896Advanced Esophageal Squamous Cell Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
Recruiting
A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain
NCT07377721Diabetic Peripheral Neuropathic Pain
Shandong Suncadia Medicine Co., Ltd.
Phase 1
168
Beijing, Chongqing
2026-03-24
Recruiting
Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer
NCT07488507Mediastinal Metastases of Lung Cancer
Third Military Medical University
Not applicable
240
Chongqing
2026-03-20
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Recruiting
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT07481786Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated, Bevacizumab
Sun Yat-sen University
Phase 3
220
Chongqing, Guangzhou
2026-03-20
Recruiting
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
NCT07398859Seasonal Allergic Rhinitis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
300
Beijing, Chongqing, Baoding, Cangzhou, Langfang, Shijiazhuang, Zhangjiakou, Zhengzhou
2026-03-19
Recruiting
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
NCT07412691Skin Diseases
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
MK-3475AยฑCalderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT07431827Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Shantou, Shenzhen, Zhengzhou, Jingzhou, Wuhan
2026-03-16
Not yet open
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
NCT07418372Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria, Pertussis
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 1/2
660
Chongqing
2026-03-12
Recruiting
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
NCT06951646Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
Anqing, Suzhou, Beijing, Chongqing, Lanzhou, Shijiazhuang, Tangshan, Xingtai
2026-03-10
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
CAS for Stenosis With High-risk Features for CEA
NCT07370246Carotid Artery Stenosis, Carotid Artery Stenting
Beijing Tiantan Hospital
Not applicable
212
Beijing, Chongqing, Nanning, Guiyang, Shijiazhuang, Xingtai, Wuhan, Hohhot
2026-03-06
Not yet open
Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma
NCT07453771Allergic Rhinitis, Asthma
The Affiliated Hospital of Qingdao University
Not applicable
18
Guangzhou, Qingdao, Taiโ€™an, Chongqing
2026-03-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Not yet open
Clinical Study of Trap-(FAPI)3 PET Imaging in the Diagnosis of Pulmonary Nodules
NCT07448441Lung Nodules
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
50
Chongqing
2026-03-01
Not yet open
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
NCT07347626Acute Ischemic Stroke
Xinqiao Hospital of Chongqing
Phase 3
786
Chongqing, Haikou, Ganzhou, Jiโ€™an, Nanchang
2026-03-01
Recruiting
Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy
NCT07452848Gallbladder Diseases, Cholelithiasis
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Not yet open
AI Models in Clinical Pathology Diagnosis: A Multicenter RCT
NCT07408167Pathology Foundation Model
Nanfang Hospital, Southern Medical University
Not applicable
2,060
Chongqing, Guangzhou, Zhengzhou
2026-03-01
Not yet open
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases
NCT07459205Pulmonary Fibrosis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
50
Chongqing
2026-03-01
Not yet open
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
800
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2026-03
Not yet open
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684HER2 IHC3+ Advanced Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Not yet open
Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss
NCT07404709Sudden Hearing Loss, Extracellular Vesicles
The Affiliated Hospital of Qingdao University
Phase 1/2
9
Guangzhou, Qingdao, Taiโ€™an, Chongqing
2026-02-28
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
Recruiting
Single-ascending Dose Study of HEC-151 Injection
NCT07376200Healthy Adult Male
Sunshine Lake Pharma Co., Ltd.
Phase 1
81
Chongqing, Bishan
2026-02-24
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
NCT07378527Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
344
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang
2026-02-13
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT06059261Nasopharyngeal Carcinoma
Chongqing University Cancer Hospital
Phase 2
30
Chongqing
2026-02-09
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
NCT07421258Crohn's Disease, Ulcerative Colitis
AbbVie
Observational
2,000
Chongqing
2026-02-09
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Not yet open
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
NCT07440212Esophagus Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
50
Chongqing
2026-02-01
Not yet open
An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture
NCT07409870Ureteral Stricture, Ureteral Obstruction, Microbiome, Metabolomics
First Affiliated Hospital of Chongqing Medical University
Observational
120
Chongqing
2026-02-01
Recruiting
Study of CD19 CAR-T Therapy for Refractory SLE
NCT07403097Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Chongqing
2026-02
Recruiting
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
NCT07552012Active Non-anterior, Non-infectious Uveitis
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
40
Chongqing
2026-01-29
Recruiting
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642Severe Asthma
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600Locally Advanced Breast Cancer, Metastatic Breast Cancer
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Changchun, Wenzhou, Beijing, Chengdu, Chongqing, Guangzhou
2026-01-21
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562Small for Gestational Age
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Active, closed
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
NCT07230119Overweight , Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 3
755
Xuancheng, Beijing, Chongqing, Lanzhou, Guangzhou, Huizhou, Nanning, Handan
2026-01-16
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Recruiting
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT07297212Recurrent Glioblastoma
BioNTech SE
Phase 2
75
Beijing, Chongqing, Jinan, Shanghai, Shenzhen, Wuhan
2026-01-15
Recruiting
Prediction Model for MINS After Major Hepatobiliary Surgery
NCT07335042Myocardial Injury After Noncardiac Surgery (MINS), Postoperative Complications, Liver Neoplasm, Hepatobiliary Diseases
Beijing Tsinghua Chang Gung Hospital
Observational
1,800
Beijing, Chongqing, Qingdao, Shandong, Zhuhai
2026-01-14
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS
NCT07298889Noninvasive Ventilation, Pneumonia, ARDS
Chongqing Medical University
Not applicable
706
Chongqing
2026-01-04
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Not yet open
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
Peking University People's Hospital
Observational
4,000
Beijing, Chongqing, Hangzhou, Harbin, Tianjin, Wuhan
2026-01-01
Recruiting
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT07349498Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events
Peking University People's Hospital
Observational
10,000
Beijing, Chongqing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Xi'an
2026-01-01
Not yet open
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
NCT07376876Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
73
Chongqing
2026-01-01
Not yet open
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
NCT07324473Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
First Affiliated Hospital of Chongqing Medical University
Phase 2
65
Chongqing
2026-01-01
Not yet open
Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control
NCT07330180Myopia, Myopia, Progressive
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
364
Chongqing, Foshan, Zhengzhou, Wuhan, Shenyang, Guilin, Xiโ€™an
2026-01-01
Recruiting
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
Shanghai Jiao Tong University School of Medicine
Phase 2
300
Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun
2026-01-01
Not yet open
Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification
NCT07199101Radiation Dose Reduction
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Active, closed
The Clinical Application Study of Obinutuzumab in Pediatric Refractory Nephrotic Syndrome
NCT07612592Primary Nephrotic Syndrome
Children's Hospital of Chongqing Medical University
Observational
100
Chongqing
2026-01-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Recruiting
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
NCT07203144Depression - Major Depressive Disorder
First Affiliated Hospital of Chongqing Medical University
Phase 2
172
Chongqing
2025-12-31
Not yet open
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
NCT07326878Hand, Foot and Mouth Disease (HFMD), HFMD, Hand, Foot and Mouth Disease
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 1
144
Chongqing
2025-12-30
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Not yet open
Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture
NCT07279220Femoral Artery Puncture, Vascular Closure Device, Hemostasis
Shanghai Bomaian Medical Technology Co., Ltd
Not applicable
238
Chongqing
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Rows per page Showing 101–200 of 1056
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chongqing?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,056 of those studies with a site in Chongqing.

How many clinical trials are recruiting in Chongqing?

589 of the 1,056 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 118 have not yet opened recruitment, 334 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.